Evaluating a test to predict benefits of extended hormone therapy for breast cancer
Official title: Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
Funded at University of Tx Md Anderson Can Ctr · NIH-10932233 · Data updated 2026-11-12
This study is looking at a special test that checks how well breast cancer tumors respond to hormone therapy, so doctors can better recommend treatment for patients who have finished five years of initial therapy and may benefit from continuing it to improve their chances of staying cancer-free.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 20, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $351,809 |
| NIH project number | 5UH3CA276603-02 |
| Project ID | NIH-10932233 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are breast cancer patients who have completed five years of adjuvant endocrine therapy and are considering extended treatment.
✕Less likely to help
Patients who have not undergone endocrine therapy or those with non-hormone receptor-positive breast cancer may not benefit from this research.
What this research studies
This research investigates the SET ER/PR assay, which measures how sensitive breast cancer tumors are to endocrine therapy by analyzing tumor samples. The assay aims to predict which patients will benefit from an extended duration of hormone therapy after initial treatment. By correlating receptor activity with treatment response, the study seeks to provide personalized treatment recommendations for patients who have completed five years of adjuvant endocrine therapy. The findings could help improve disease-free survival rates for breast cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment plans for breast cancer patients, potentially improving their long-term outcomes.
How similar studies have gone: Previous research has shown promising results with similar assays in predicting treatment responses, indicating a potential for success in this approach.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Symmans, William F — University of Tx Md Anderson Can Ctr
- Study coordinator: Symmans, William F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.